BLA 761061 · Janssen Biotech
Tremfya
Guselkumab · Injection · Interleukin-23 Antagonist
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: May 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jul 13, 2017
Approved uses
10
Original approval plus efficacy supplements
Registered trials
93
38 Phase 3, 30 recruiting
FAERS reports
38,224
9,624 serious, 482 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 20, 2026.
TREMFYA is an interleukin-23 antagonist indicated for the treatment of: adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. ( 1.2 ) adults with moderately to severely active ulcerative colitis. ( 1.3 ) adults with moderately to severely active Crohn's disease. ( 1.4 ) 1.1 Plaque Psoriasis TREMFYA is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate-to-severe plaque psoriasis and who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis TREMFYA is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. 1.3 Ulcerative Colitis TREMFYA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis. 1.4 Crohn's Disease TREMFYA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease.
Mechanism: Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Guselkumab inhibits the release of proinflammatory cytokines and chemokines.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 28, 2026 Supplement 34 · Efficacy LetterLabelMedication Guide
- Sep 26, 2025 Supplement 29 · Efficacy LabelLetter
- Sep 26, 2025 Supplement 28 · Efficacy LabelLetter
- Sep 19, 2025 Supplement 26 · Efficacy LabelLetter
- Mar 20, 2025 Supplement 24 · Efficacy · priority review LabelLetter
- Sep 11, 2024 Supplement 21 · Efficacy · priority review LabelLetterReview
- Jul 13, 2020 Supplement 7 · Efficacy LabelLetterReview
- Nov 22, 2019 Supplement 4 · Efficacy LetterLabel
- Jan 29, 2019 Supplement 1 · Efficacy LetterLabel
- Jul 13, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- TREMFYA · GUSELKUMAB 100MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Guselkumab" as an intervention, any sponsor and status, largest first.
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03466411 · 1,409 participants · Start Apr 13, 2018 · Primary completion Oct 20, 2023
Drug: Guselkumab Dose 1; Guselkumab Dose 2 and 6 more · For: Crohn's Disease
Sites: Dothan, Alabama; Mobile, Alabama; Tucson, Arizona · 579 sites in all
- A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04033445 · 1,064 participants · Start Sep 26, 2019 · Primary completion Sep 19, 2023
Drug: Placebo; Guselkumab · For: Ulcerative Colitis
Sites: Lancaster, California; Los Angeles, California; Colorado Springs, Colorado · 392 sites in all
- A Study of Guselkumab in Participants With Active Psoriatic ArthritisPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04882098 · 1,054 participants · Start Jun 17, 2021 · Primary completion Dec 30, 2024
Drug: Guselkumab; Placebo · For: Arthritis, Psoriatic
Sites: Birmingham, Alabama; Flagstaff, Arizona; Glendale, Arizona · 280 sites in all
- A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type PsoriasisPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03090100 · 1,048 participants · Start Apr 27, 2017 · Primary completion Aug 2, 2018
Drug: Guselkumab; Placebo and 1 more · For: Psoriasis
Sites: Birmingham, Alabama; Los Angeles, California; Oceanside, California · 142 sites in all
- A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque PsoriasisPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03573323 · 1,027 participants · Start Nov 9, 2018 · Primary completion Jul 15, 2019
Drug: Ixekizumab; Guselkumab and 1 more · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 124 sites in all
- A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and RetreatmentPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02207244 · 992 participants · Start Nov 3, 2014 · Primary completion Oct 1, 2015
Drug: Guselkumab 100 mg; Placebo for guselkumab and 2 more · For: Psoriasis
Sites: Birmingham, Alabama; Bakersfield, California; Los Angeles, California · 93 sites in all
- A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type PsoriasisPivotal-lookingCompleted
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
NCT03818035 · 880 participants · Start Feb 8, 2019 · Primary completion Mar 7, 2022
Drug: Guselkumab; Placebo Injection · For: Psoriasis
Sites: Antony, France; Auxerre, France; Bezanne, France · 90 sites in all
- A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to UstekinumabPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02203032 · 872 participants · Start Oct 7, 2014 · Primary completion Dec 25, 2015
Drug: Ustekinumab; Guselkumab and 2 more · For: Psoriasis
Sites: Birmingham, Alabama; Bakersfield, California; Los Angeles, California · 85 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue12,395
- accidental exposure to product3,707
- drug ineffective2,587
- needle issue2,480
- psoriasis2,311
- device issue2,150
- device deployment issue1,793
- device malfunction1,772
- off label use1,650
- product storage error1,218
- device defective1,207
- inappropriate schedule of product administration1,118
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 84 |
| 2018 | 1,199 |
| 2019 | 2,087 |
| 2020 | 2,193 |
| 2021 | 3,115 |
| 2022 | 5,058 |
| 2023 | 5,778 |
| 2024 | 5,014 |
| 2025 | 6,820 |
| 2026 | 6,874 |
Recalls
1 FDA enforcement reports for this application.
Mar 9, 2021 · Class III · Terminated
Temperature Abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tremfya* (Guselkumab)
2024 spending
$619M
Beneficiaries
10,848
46,079 claims
Per beneficiary
$57,041
$13,250.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $167,392,578 |
| 2021 | $285,251,577 |
| 2022 | $439,124,671 |
| 2023 | $531,497,098 |
| 2024 | $618,784,543 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis.
Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology 2024 · Systematic Review, Comparative Study
- Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Feagan BG, Sands BE, Sandborn WJ, et al. · Lancet Gastroenterol Hepatol 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, et al. · Cochrane Database Syst Rev 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis.
Shehab M, Alrashed F, Alsayegh A, et al. · Clin Gastroenterol Hepatol 2025 · Systematic Review, Comparative Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.